103 related articles for article (PubMed ID: 25395141)
1. HiJAKing T-ALL.
Asnafi V
Blood; 2014 Nov; 124(20):3038-40. PubMed ID: 25395141
[TBL] [Abstract][Full Text] [Related]
2. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
3. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
4. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
[TBL] [Abstract][Full Text] [Related]
5. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
7. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
8. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.
Bellanger D; Jacquemin V; Chopin M; Pierron G; Bernard OA; Ghysdael J; Stern MH
Leukemia; 2014 Feb; 28(2):417-9. PubMed ID: 24048415
[No Abstract] [Full Text] [Related]
9. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
10. Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Broux M; Prieto C; Demeyer S; Vanden Bempt M; Alberti-Servera L; Lodewijckx I; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J
Blood; 2019 Oct; 134(16):1323-1336. PubMed ID: 31492675
[TBL] [Abstract][Full Text] [Related]
11. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.
Batista CR; Lim M; Laramée AS; Abu-Sardanah F; Xu LS; Hossain R; Bell GI; Hess DA; DeKoter RP
Blood Adv; 2018 Nov; 2(21):2798-2810. PubMed ID: 30355579
[TBL] [Abstract][Full Text] [Related]
12. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
13. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
Sams MP; Iansavitchous J; Astridge M; Rysan H; Xu LS; Rodrigues de Oliveira B; DeKoter RP
J Pharmacol Exp Ther; 2024 Mar; 389(1):40-50. PubMed ID: 38336380
[TBL] [Abstract][Full Text] [Related]
14. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Riera L; Lasorsa E; Bonello L; Sismondi F; Tondat F; Di Bello C; Di Celle PF; Chiarle R; Godio L; Pich A; Facchetti F; Ponzoni M; Marmont F; Zanon C; Bardelli A; Inghirami G
Leuk Lymphoma; 2011 Sep; 52(9):1742-50. PubMed ID: 21599579
[TBL] [Abstract][Full Text] [Related]
15. Role of JAK1, JAK2, and JAK3 in Functional Stimulation of Mesenchymal Precursor Cells by Alkaloid Songorine.
Zyuz'kov GN; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM; Chaikovskii AV; Agafonov VI; Zhdanov VV
Bull Exp Biol Med; 2017 Aug; 163(4):443-446. PubMed ID: 28853089
[TBL] [Abstract][Full Text] [Related]
16. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
17. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
18. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
19. Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.
Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM
Bull Exp Biol Med; 2016 Dec; 162(2):240-243. PubMed ID: 27905037
[TBL] [Abstract][Full Text] [Related]
20. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]